NASDAQ:APVO Aptevo Therapeutics 3/26/2026 Earnings Report $5.00 +0.14 (+2.88%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aptevo Therapeutics EPS ResultsActual EPS$118.23Consensus EPS -$8.10Beat/MissBeat by +$126.33One Year Ago EPSN/AAptevo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAptevo Therapeutics Announcement DetailsQuarterDate3/26/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsAptevo Therapeutics' next earnings date is estimated for Thursday, May 21, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Aptevo Therapeutics Earnings HeadlinesAptevo Therapeutics Inc APVOMay 6 at 9:00 PM | morningstar.comMAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 ...May 6 at 9:00 PM | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 8 at 1:00 AM | InvestorPlace (Ad)Aptevo Therapeutics (APVO) price target decreased by 99.72% to 21.42March 28, 2026 | msn.comAptevo Therapeutics: Aptevo Provides State of the Business Report and 2025 Financial ResultsMarch 26, 2026 | finanznachrichten.deAptevo Therapeutics: Aptevo to Participate in March 2026 ConferencesMarch 19, 2026 | finanznachrichten.deSee More Aptevo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aptevo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your email. Email Address About Aptevo TherapeuticsAptevo Therapeutics (NASDAQ:APVO), Inc. is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system. The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life. Key product candidates in Aptevo’s pipeline include AFM13, a CD30/CD16A innate cell engager in development for CD30-positive lymphomas, and APVO436, a bispecific molecule targeting CD123 and CD3 for acute myeloid leukemia. Aptevo Therapeutics conducts clinical studies across North America and Europe, partnering with academic centers and industry collaborators to advance its lead candidates through Phase 1/2 trials. The company’s approach emphasizes dual activation of innate and adaptive immune responses to achieve potent antitumor effects while reducing the risk of off-target toxicity. Guided by a management team with extensive experience in biologic drug development and cell-based therapies, Aptevo continues to expand its pipeline and seek strategic partnerships to bring its immunotherapeutic candidates to patients with high-unmet medical needs.View Aptevo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% Rally Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
